Liposarcoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Liposarcoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ Wed, 29 Apr 2026 14:59:55 +0000 https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ This clinical trial studies a treatment for soft tissue sarcoma, a type of cancer that develops in soft tissues like muscles and fat. The study focuses on patients whose cancer has spread to other parts of the body (metastatic) or who did not respond well to previous treatments. The trial compares two treatment approaches: one using only trabectedin (a chemotherapy medication) and another combining trabectedin with tTF-NGR (an experimental drug).

The study aims to determine if adding tTF-NGR to standard trabectedin treatment helps keep the cancer under control for a longer time. Both medications are given through an intravenous infusion directly into the bloodstream. The experimental drug tTF-NGR is designed to concentrate the chemotherapy medication inside the tumor.

During the study, participants receive treatment for up to 360 days. Some patients will receive only trabectedin, while others will receive both trabectedin and tTF-NGR. Regular medical examinations and imaging tests will be performed to monitor how the cancer responds to the treatment. The study focuses on patients whose tumors show a specific characteristic called CD13 positivity, which is determined through laboratory testing.

]]> Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma https://clinicaltrials.eu/trial/study-comparing-bi-907828-and-doxorubicin-for-patients-with-advanced-dedifferentiated-liposarcoma/ Wed, 29 Apr 2026 14:59:49 +0000 https://clinicaltrials.eu/trial/study-comparing-bi-907828-and-doxorubicin-for-patients-with-advanced-dedifferentiated-liposarcoma/ This clinical trial is focused on studying a type of cancer called dedifferentiated liposarcoma, which is an advanced form of cancer that develops in fat cells. The study aims to compare the effectiveness of a new treatment called brigimadlin (BI 907828) with an existing chemotherapy drug known as doxorubicin. Brigimadlin is taken as a film-coated tablet, while doxorubicin is given as a solution for infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of the study is to determine if brigimadlin is more effective than doxorubicin as a first-line treatment for patients with advanced or metastatic dedifferentiated liposarcoma. Participants in the study will be randomly assigned to receive either brigimadlin or doxorubicin. The study will monitor the progression of the disease and assess the overall survival of the participants. The treatment period for brigimadlin is up to 21 days, while doxorubicin can be administered for a longer period, up to 126 days.

Throughout the study, participants will undergo regular assessments to track their response to the treatment. These assessments will include monitoring for any side effects and evaluating the quality of life through specific questionnaires. The study will also collect blood samples to analyze the drug’s effects on the body and any changes in the tumor. The ultimate goal is to find a more effective treatment option for patients with this challenging type of cancer.

]]> Study of Pemigatinib and Retifanlimab for Patients with Advanced Dedifferentiated Liposarcoma https://clinicaltrials.eu/trial/study-of-pemigatinib-and-retifanlimab-for-patients-with-advanced-dedifferentiated-liposarcoma/ Wed, 29 Apr 2026 14:26:43 +0000 https://clinicaltrials.eu/trial/study-of-pemigatinib-and-retifanlimab-for-patients-with-advanced-dedifferentiated-liposarcoma/ This clinical trial is focused on studying a type of cancer called dedifferentiated liposarcoma, which is a rare form of cancer that develops in fat cells. The study is testing two treatments: Pemigatinib, which is taken as a tablet, and Retifanlimab (also known by its code name INCMGA00012), which is given as a solution through an intravenous infusion. The purpose of the study is to evaluate the potential benefits of these treatments for patients with advanced dedifferentiated liposarcoma.

Participants in the study will receive either the active treatments or a placebo. The study will monitor the progression of the disease over a period of time, looking at how long patients live without the disease getting worse and how their bodies respond to the treatments. The study will also assess the overall survival of patients, which means the length of time patients live from the start of the treatment. Additionally, the study will track any side effects or adverse events that occur during the treatment period.

The trial will also evaluate changes in patients’ quality of life and their ability to perform daily activities. This will be done using a questionnaire designed to measure these aspects. The study aims to provide valuable information on the effectiveness and safety of Pemigatinib and Retifanlimab in treating advanced dedifferentiated liposarcoma, potentially leading to improved treatment options for patients with this condition.

]]>